Figure 7.

Dipyridamole supplementation alleviates DHEA-induced hyperandrogenism symptoms and regulates HSP90α palmitoylation

(A) Representative hematoxylin-eosin (H&E)-stained sections from the ovaries of the control, DHEA, and DHEA + dipyridamole (DIP) groups. Scale bar: 200 μm. The asterisk (∗) represents the corpus luteum, and the pound sign (#) represents the ovary vacuoles.

(B) Representative estrous cycles.

(C) Serum estradiol levels in the control (black plots), DHEA (red plots), and DHEA + DIP (blue plots) groups (n = 10 mice per group).

(D) Testosterone levels in the serum of the control (black plots), DHEA (red plots), and DHEA + DIP (blue plots) groups (n = 10 mice per group).

(E) LH levels in the serum of the control (black plots), DHEA (red plots), and DHEA + DIP (blue plots) groups (n = 10 mice per group).

(F) FSH levels in the serum of the control (black plots), DHEA (red plots), and DHEA + DIP (blue plots) groups (n = 10 mice per group).

(G) Endogenous HSP90α palmitoylation levels were detected with the indicated concentration of DIP treatment for 4h in the presence of HAM. (H) HSP90α palmitoylation levels were detected in mouse ovarian tissues from the control, DHEA, and DHEA + DIP groups (n = 4 mice per group) in the presence of HAM. For (C, E and F), p values were determined by a two-tailed Mann–Whitney Wilcoxon test, and the data are presented as the mean values ± SEMs. For (D), p values were determined by two-tailed Student’s t test, and the data are presented as the mean values ± SEMs.